KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to -$28.4 million.

  • Halozyme Therapeutics' Other Working Capital Changes fell 40567.51% to -$28.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $33.0 million, marking a year-over-year increase of 71534.73%. This contributed to the annual value of $33.0 million for FY2025, which is 71534.73% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Other Working Capital Changes is -$28.4 million, which was down 40567.51% from $20.3 million recorded in Q3 2025.
  • Halozyme Therapeutics' Other Working Capital Changes' 5-year high stood at $43.5 million during Q2 2024, with a 5-year trough of -$38.5 million in Q3 2024.
  • For the 5-year period, Halozyme Therapeutics' Other Working Capital Changes averaged around $2.2 million, with its median value being $1.8 million (2021).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first tumbled by 332384.11% in 2023, then surged by 99447.41% in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Other Working Capital Changes stood at $5.0 million in 2021, then tumbled by 205.02% to -$5.3 million in 2022, then skyrocketed by 122.68% to $1.2 million in 2023, then plummeted by 568.03% to -$5.6 million in 2024, then tumbled by 405.68% to -$28.4 million in 2025.
  • Its Other Working Capital Changes stands at -$28.4 million for Q4 2025, versus $20.3 million for Q3 2025 and $36.1 million for Q2 2025.